Navigation Links
VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual,Meeting

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--May 9, 2007 - Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced positive results from several studies evaluating the VEGF Trap-Eye in the neovascular form of age-related macular degeneration (wet AMD) and diabetic macular edema (DME). These findings were presented this week at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The data reported at the meeting from a pre-planned interim analysis of a Phase 2 randomized study of the VEGF Trap-Eye in patients with wet AMD and a Phase 1 DME trial are available on the Regeneron website (www.regeneron.com on the Events page, under the Investor Relations heading).

"We are very encouraged by the preliminary observation in the Phase 2 wet AMD trial that the most intense dosing regimen studied, 2 milligrams delivered by intravitreal injection every 4 weeks, resulted in an average gain of more than 10 letters after 12 weeks of treatment," said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories. "Perhaps equally important is that after receiving only a single dose of the VEGF Trap-Eye, patients on average had an improvement in the number of letters read both 8 and 12 weeks after treatment. Although significantly more clinical testing is required, the VEGF Trap-Eye may offer the potential to improve vision in patients with wet AMD with a regular dosing regimen that is less frequent than monthly."

Regeneron and Bayer HealthCare AG plan to initiate the VEGF Trap-Eye Phase 3 program in wet AMD in the third quarter of 2007. In the first Phase 3 trial, the companies currently plan to evaluate the VEGF Trap-Eye using 4 and 8 week dosing intervals in direct comparison with ranibizumab (Lucentis(R), a registered trademark of Genentech, Inc.) administered every 4 weeks according to its label. The companies are collaborating on the global development of the VE
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: VEGF Trap Eye Phase Wet AMD Results Reported ARVO Annual Meeting
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:7/9/2014)... 10, 2014 -- The World Health Organization recommends that ... moderate to vigorous physical activity (MVPA) each day. ... MVPA during school hours. Therefore, it stands to ... increase MVPA. In a new study scheduled for ... confirmed that time spent outdoors after school was positively ...
(Date:7/9/2014)... After Susan Wakulich was told she had an aneurysm, she ... of her. , "I was devastated," said Wakulich, who is ... knew this was a serious diagnosis. Then I met Dr. ... involved a less invasive procedure. It was something I didn,t ... in a multi-center U.S. clinical trial to evaluate the safety ...
(Date:7/9/2014)... findings from Fox Chase Cancer Center paint a relatively ... of breast cancers that have spread to the chest ... that grow into the skin, regardless of size and ... as stage III and called "locally advanced" tumors, ... cancer, often with poor survival. Locally advanced breast cancers ...
(Date:7/9/2014)... By looking at ... structure and function, personality, life experiences and genetics, researchers can ... binge drinking within the next two years. Impulsivity, hopelessness, sensation-seeking ... events and a family history of drug use contribute to ... child had had a single drink at age 14 was ...
(Date:7/9/2014)... reputation for being highly toxic, but when used in the ... to offer potential health benefits in a range of issues, ... compound (AP39), designed and made at the University of Exeter, ... of very small amounts of the substance to the right ... have already found that the compound protects mitochondria the ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:New type of stent could help some brain aneurysm patients 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:What drives a child to abuse alcohol? 2Health News:Rotten egg gas holds key to healthcare therapies 2
... 20, 2011) When two adjacent discs in the low ... or other symptoms, replacement with artificial discs can be a ... data from a randomized, multicenter trial recently published in the ... studies have compared single-disc replacement with fusion but this is ...
... All children should be screened for high cholesterol when they,re ... the National Lipid Association. The group also urges that ... elevated cholesterol be screened for cholesterol with a simple blood ... people know if a history of high cholesterol runs in ...
... (HealthDay News) -- People who have psoriasis and hypertension are ... more medications to control it, a new study suggests. ... causes itchy, thickened, dry, red patches on the skin. ... 835 patients who had psoriasis and hypertension. Their cases were ...
... as follows: SESSION I / Monday, May 23 ... Rates of Acute Coronary Syndrome Patients in Real World Clinical ... Gandhi SK2, Bhandary D2, Stephenson JJ1, Gold A2, Fu AC1, ... Wilmington, Del. SESSION II / Tuesday, May 24 ...
... Aage Moller of UT Dallas is known throughout the world ... But back at The University of Texas at Dallas, he,s ... Moller received the President,s Teaching Excellence Award for Tenure-Track ... was selected from among more than 100 eligible faculty members ...
... provides evidence for significant differences between new and old ... a cheap, rapid and effective way to monitor the ... preservatives, blood stored in banks continues to age, resulting ... subsequent changes to cell properties and function. There ...
Cached Medicine News:Health News:2-year results: Artificial disc a viable alternative to fusion for 2-level disc disease 2Health News:Experts Say Cholesterol Screenings Should Start in Childhood 2Health News:Psoriasis, High Blood Pressure May Be Linked 2Health News:HealthCore presents ISPOR poster sessions 2Health News:UT Dallas' Moller receives teaching award 2Health News:Research provides insight into quality of stored blood used for transfusions 2Health News:Research provides insight into quality of stored blood used for transfusions 3
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
... Jaguar Lumbar I/F Cage system is a ... separate the mechanical and biologic functions of ... Lumbar I/F Cage provides a device designed ... and uses autologous cancellous bone, the best ...
... transmitted through sorted fiberglass bundles ... transmit it to a user's ... designed for rough, industrial handling ... low cost if they should ...
The original Zeppelin High-Speed Motordrill System has been developed to rapidly cut bone, plastic and metal with utmost precision. 120-150 psi - 90.000 rpm - 90g - autoclavable at <134 C....
Medicine Products: